A Safety and Tolerability Study of Belumosudil (KD025) Treatment in Subjects With Moderately Severe Psoriasis Vulgaris
NCT02106195 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 8
Last updated 2022-03-23
Summary
The primary objective is to assess the safety and tolerability of 200 mg of belumosudil administered orally once daily for 28 days.
Conditions
- Psoriasis Vulgaris
Interventions
- DRUG
-
Belumosudil
Sponsors & Collaborators
-
Kadmon Corporation, LLC
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-04-30
- Primary Completion
- 2014-09-30
- Completion
- 2014-09-30
Countries
- United States
Study Locations
More Related Trials
-
Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis
NCT02931838 ·Status: COMPLETED ·Phase: PHASE2
-
A Safety Study of Ustekinumab in the Treatment of Pediatric Participants Aged 6 Years and Older With Moderate to Severe Plaque Psoriasis
NCT03218488 ·Status: ACTIVE_NOT_RECRUITING
-
A Study of BMS-582949 in Patients With Moderate to Severe Plaque Psoriasis
NCT00399906 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis
NCT03025542 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 1 Study of CC-90005 in Healthy Subjects and Subjects With Moderate to Severe Plaque-type Psoriasis
NCT02502188 ·Status: TERMINATED ·Phase: PHASE1
-
Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00646191 ·Status: COMPLETED ·Phase: PHASE2
-
A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT03410992 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis
NCT05730725 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Determine the Optimal Dose of Tildrakizumab (SCH 900222/MK-3222) for the Treatment of Moderate-to-severe Chronic Plaque Psoriasis (P05495) (MK-3222-003)
NCT01225731 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Investigate Efficacy and Safety of KBL697 in Patients with Moderate Plaque Type Psoriasis
NCT04911751 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis
NCT04718896 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00195676 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of UCB4940 in Patients With Psoriasis
NCT02529956 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis
NCT04123795 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Safety Study of BMS-986165 in Healthy Subjects and to Treat Psoriasis
NCT02534636 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment
NCT02207244 ·Status: COMPLETED ·Phase: PHASE3
-
Study of BMS-587101 in Patients With Moderate to Severe Psoriasis
NCT00162253 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to Stelara® in Subject With Moderate to Severe Plaque Psoriasis
NCT04967508 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy
NCT04263610 ·Status: COMPLETED ·Phase: PHASE4
-
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis
NCT06039189 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis
NCT02561806 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis
NCT02207231 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis.
NCT02425826 ·Status: COMPLETED ·Phase: PHASE4
-
Randomized Double-Blind Placebo-Controlled Trial Using Recombinant Human Interleukin-10 for Moderate-to-Severe Psoriasis
NCT00001797 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis
NCT03504852 ·Status: COMPLETED ·Phase: PHASE3